Regulation & Compliance

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Universal Insurance Holdings announces a new $20M stock buyback, signaling strong financial health and confidence amidst a stabilizing Florida market.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

Evergy is repurchasing $244M of its convertible notes, a strategic play to reduce future stock dilution and manage complex arbitrage market ripples.

A new blood test in Western Canada promises to detect 59 cancers early. But with a high price tag and pending approval, it raises critical questions.

The banking giant's investment in clearinghouse Ubyx signals a major shift towards mainstream adoption of tokenized deposits and stablecoins.

China's Baidu secures Dubai's first fully driverless permit, launching a new operations hub and setting the stage for a 1,000-vehicle robotaxi fleet.

As it exits its startup phase, Integro Bank names founder Jim Malerba as Acting CEO to lead its next chapter of strategic, risk-managed expansion.

As QCR Holdings prepares to release its Q4 and full-year 2025 financials, investors watch for clues on regional economic resilience and strategic growth.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

Ervin Cohen & Jessup merges with Carico McDonald Kil & Benz, adding a top-tier team and a new Beach Cities office to bolster its West Coast presence.

A new nationwide study reveals a massive gap in care for heart failure patients, costing lives and billions. Why are proven, cheap medications being overlooked?

The digital ad industry's standard-bearer unveils a plan to scale AI agents by upgrading existing protocols, aiming for interoperability over fragmentation.

The world's biggest music and AI giants partner to revolutionize music discovery and creation, promising an artist-centric approach to end generic AI content.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

AP automation firm Charted launches a UK office, betting its integration-free platform can solve Europe's complex, multi-currency financial challenges.

With AI reshaping cybersecurity, Ping Identity appoints Adnan Chaudhry as CRO to scale its trusted identity solutions for a new digital landscape.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

TwelveStone Health Partners and AI firm Tennr are teaming up to automate patient referrals, aiming to slash wait times and improve access to vital care.